Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study.
Saved in:
| Title: | Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study. |
|---|---|
| Authors: | Bahlis, Nizar J.1 (AUTHOR) nbahlis@ucalgary.ca, Zonder, Jeffrey2 (AUTHOR), Karlin, Lionel3 (AUTHOR), Plesner, Torben4 (AUTHOR), Paris, Laura5 (AUTHOR), Wrobel, Tomasz6 (AUTHOR), Hungria, Vania7 (AUTHOR), Besemer, Britta8 (AUTHOR), Crusoe, Edvan9 (AUTHOR), Silkjaer, Trine10 (AUTHOR), Perrot, Aurore11 (AUTHOR), Moreau, Philippe12 (AUTHOR), Wu, Ka Lung13 (AUTHOR), Delimpasi, Sosana14 (AUTHOR), Dimopoulos, Meletios A.15,16 (AUTHOR), Levin, Mark-David17 (AUTHOR), Mangiacavalli, Silvia18 (AUTHOR), Nnane, Ivo19 (AUTHOR), Kim, Yu Jin20 (AUTHOR), Krevvata, Maria19 (AUTHOR) |
| Source: | Leukemia & Lymphoma. Dec2025, Vol. 66 Issue 14, p2685-2696. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
